The DNMT3A Knockout AGS Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the DNMT3A gene has been disrupted. This product provides a mixed population of edited cells, ideal for studying gene function without clonal selection artifacts. It serves as a loss-of-function model for investigating de novo DNA methylation and epigenetic regulation in a gastric cancer context.
The AGS human gastric adenocarcinoma cell line serves as a well-characterized model system for studying gastric epithelial biology and gastric cancer pathogenesis. Originally derived from a patient tumor, AGS cells are adherent, epithelial in morphology, and possess a modal chromosome number of 49, reflecting the genetic abnormalities common in gastric cancers. These cells are widely employed to investigate signaling pathways, drug responses, and epigenetic mechanisms underlying gastric carcinogenesis.
DNMT3A encodes a DNA methyltransferase that catalyzes de novo cytosine methylation at CpG sites, a process essential for establishing and maintaining epigenetic gene silencing. Its activity is modulated by upstream signals including inflammatory cytokines such as IL-6 and IL-1??, transcription factors NF-??B, STAT3, and Sp1, as well as oncogenic RAS/MAPK and PI3K/AKT pathways. DNMT3A functions in complex with DNMT3L and interacts with chromatin modifiers like HDAC1, HDAC2, and EZH2 to mediate transcriptional repression. Key downstream targets of DNMT3A-mediated methylation include tumor suppressor genes CDH1, CDKN2A, RUNX3, MLH1, and RASSF1A, whose silencing contributes to oncogenic transformation. The enzyme works in concert with DNMT1 and DNMT3B, utilizing S-adenosylmethionine (SAM) as the methyl donor, and is recognized by methyl-CpG-binding proteins such as MBD1 and MeCP2 to enforce repressive chromatin states.
In AGS gastric cancer cells, CRISPR/Cas9-mediated disruption of DNMT3A abrogates de novo DNA methylation, resulting in the derepression of epigenetically silenced tumor suppressor genes. This reactivation can restore expression of proteins such as E-cadherin (CDH1) and p16INK4a (CDKN2A), and may attenuate the malignant phenotype by reducing proliferation, increasing apoptosis, or impairing invasive capacity. Consequently, the DNMT3A knockout polyclonal population serves as a powerful tool to dissect the role of aberrant DNA methylation in gastric cancer maintenance and progression.
Researchers can employ these polyclonal knockout cells in a wide array of experimental paradigms. For instance, they are ideally suited for global DNA methylation analysis via bisulfite sequencing, transcriptomic profiling by RNA-seq to identify methylation-dependent gene networks, and functional validation of candidate tumor suppressors. Drug discovery programs may use this model to test the efficacy of DNA methyltransferase inhibitors or to screen for epigenetic modulators in gastric cancer. Additional common readouts include cell proliferation and colony formation assays to assess growth, flow cytometry for cell cycle distribution, and invasion assays to evaluate metastatic potential. For further details or technical support, please contact Ascent Research.
